SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001390478-23-000025
Filing Date
2023-11-09
Accepted
2023-11-09 16:07:05
Documents
13
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sls-20231109.htm   iXBRL 8-K 31977
2 EX-99.1 sls-202311098xkexhibit991.htm EX-99.1 96015
  Complete submission text file 0001390478-23-000025.txt   258486

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sls-20231109.xsd EX-101.SCH 1931
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sls-20231109_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sls-20231109_pre.xml EX-101.PRE 13067
7 EXTRACTED XBRL INSTANCE DOCUMENT sls-20231109_htm.xml XML 2149
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 231392366
SIC: 2834 Pharmaceutical Preparations